anjaneya lifecare (CapitalMarket) Focused on anti-malarial segment

The bulk drug player has ventured in to formulations through acquisition
Date Rating Target Price Recommendation Price Broker house
10 May 2011 25/100 -- 228-240 CapitalMarket Report

No comments:

Post a Comment